Exelixis (EXEL) Bullish View Reiterated at Leerink Following Positive CABOSUN Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St rebounds with broad gains as oil slides sharply
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Leerink Bumps PT on Exelixis (EXEL) Up to $16 Following Latest Cabozantinib Data
October 11, 2016 6:27 AM EDTLeerink is boosting its price target on Outperform-rated Exelixis (Nasdaq: EXEL) from $15 to $16 after Exelixis announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell... More
Piper Jaffray Upgrades Exelixis (EXEL) to Overweight
October 10, 2016 9:09 AM EDTPiper Jaffray upgraded Exelixis (NASDAQ: EXEL) from Neutral to Overweight.
For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.
Shares of Exelixis closed at $12.95 yesterday.
... MoreExelixis (EXEL) Announces Statistically Significant Data from Cabozantinib Phase 2 in RCC
October 10, 2016 6:16 AM EDTExelixis, Inc. (Nasdaq: EXEL) announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Principal investigator Toni K. Choueiri, M.D. will present detailed data from late-breaking CABOSUN abstract [#LBA30_PR] today in the Presidential Symposium 3 session, starting at 16:30 CEST (local Copenhagen time) / 10:30 a.m. EDT / 7:30 a.m. PDT at the European Society for Medical Oncology (ESMO) 2016, which is being held October 7 11, 2016 in Copenhagen.
CABOSUN... More
